TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Blood level of β‐HCG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemostatic time of vaginal hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean PSA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: spotting days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: study completion rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pulse wave velocity (PWV) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean adjusted total cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of QALY
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Discriminatory performance of composite risk scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visuospatial working memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: visuospatial learning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: focused attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean change in HAM-D-17 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rates on MADRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in use of proton pump inhibitors
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration of morning sickness symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid use trajectory classes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adequate intraoperative analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease of acute respiratory infections incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serum ECP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: FEV(1) decrease after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Concentric 1RM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quadriceps femoris CSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thigh soreness
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rescue medication requirement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Success rates for IANB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elevation in positive affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reduction in negative affect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean number of orgasms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of arousal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Orgasmic intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enamel remineralisation (%SMHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluoridation (EFU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants experiencing PDWI
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients receiving blood transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Units of red blood cell transfusions intraoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Units of red blood cell transfusions during hospital stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Peak oxygen uptake (peak o2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bowel Function Index (BFI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total laxative intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Constipation-specific quality of life assessments
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: percentage of recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Improvement of anxiety symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-effectiveness of training in communication skills
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: successful placement of a clip and <= 2+ MR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reduction in the time to perform the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Erythrocyte membrane fluidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total MAI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of drug-related problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postmeal fullness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nevirapine resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain and Harris hip scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year probability of developing ascites, hepatocellular carcinoma, transplantation or death
Endpoint domain: Mortality/survival
Primary endpoint: Mean radiographic bone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Response (CR) during delayed phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total blood transfusion amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Increases of intima-media thickness (IMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reductions of hs-CRP, IL-18, IL-17 and MMP9 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: baseline 25(OH)D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: achieved 25(OH)D status following supplementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MenC rSBA titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: composite clinical outcome
Endpoint domain: Mortality/survival
Primary endpoint: Length of the high-pressure zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asymmetry index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite of cardiovascular death and unplanned admission to hospital for congestive HF
Endpoint domain: Mortality/survival
Primary endpoint: Protein-bound vitamin B12 absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reductions in pain catastrophizing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tear evaporation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of reintubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of patients requiring analgesics in the first 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative FLACC scores at 4, 6, and 12 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reaching treatment goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with acceptable intubating conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Arterial Pressure (MAP) before intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reliability of OSCE checklist scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement in classification of examination grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hearing deficits at low frequencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visual function improvement in amblyopic eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality due to cardiac rupture
Endpoint domain: Mortality/survival
Primary endpoint: Length of time spent with CHWs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of coaching topics discussed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: treatment index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BQLQ (Burden of Allergic Rhinitis Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decreased spasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased pressure pain thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in plantar pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain visual analogue scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NOT-S interview and clinical examination subscale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving 5% or greater weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients achieving 10% or greater weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients showing invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Withdrawal time of SN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in oxygenation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Resolution of urticaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Absence of angioedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: median percent reduction from baseline in the average monthly seizure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number of treatment responders (patients with > or = 50% reduction in seizure rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: investigator and patient global assessments of treatment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: hematuria on postoperative day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: narcotic requirement
Endpoint domain: Adverse events/effects
Primary endpoint: Intrinsic oral clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: slower onset of action
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shorter clinical duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete healing of duodenal ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of improvement between both sides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Chronic Respiratory Questionnaire (CRQ) dyspnea domain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Complete comprehension of consent information
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Serotype-specific antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of subjects with at least a 1.4-fold increase in antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Freedom from CNS infarction at 7 days
Endpoint domain: Mortality/survival
Primary endpoint: C-reactive protein values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI signal decrease for digit 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: fMRI signal decrease for digit 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma concentrations of apricitabine and BCH-335 metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Areas under the concentration-time curves of apricitabine and BCH-335 metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of apricitabine
Endpoint domain: Adverse events/effects
Primary endpoint: Mean prostate-specific antigen value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Advanced clinical stage T3-T4 prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biopsy Gleason scores less than 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intraocular pressure control
Endpoint domain: Mortality/survival
Primary endpoint: specific functionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ischemic stroke or systemic embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incremental AUC for glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: health care utilisation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: risk of high consumption of medication
Endpoint domain: Adverse events/effects
Primary endpoint: Total x-ray dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in BMD at the femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Performance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of esophageal adenocarcinoma
Endpoint domain: Mortality/survival
Primary endpoint: Risk of esophageal squamous-cell carcinoma
Endpoint domain: Mortality/survival
Primary endpoint: proportion of patients reaching predefined target IOPs after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Plasma target attainment (PTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CSF penetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of EGF ointment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NCI-CTCAE rating of rash/acne
Endpoint domain: Adverse events/effects
Primary endpoint: NCI-CTCAE rating of itching
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of invasive postmenopausal breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Mean TSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIS-LL scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quadriceps CARs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: hamstrings CAR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: systemic norepinephrine spillover
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dietary fat intake change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fruit and vegetable intake change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 increase over baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Grade 4 toxicities (lymphopenia and thrombocytopenia)
Endpoint domain: Adverse events/effects
Primary endpoint: better survival related to strong SPARCL1 expression
Endpoint domain: Mortality/survival
Primary endpoint: Acute Respiratory Infections (ARIs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: repeated point abstinence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall nasal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of ischemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: duration of ischemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of urethral stricture
Endpoint domain: Adverse events/effects
Primary endpoint: incident diabetes risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean lymphedema volume increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tooth Decayed, Missing, Filled (CAD) index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMEF values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to achieve TOF ratio of 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from valve-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: weight loss maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient satisfaction with the education experience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Likelihood to recommend the program
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: postoperative polysomnography findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct localization of parathyroid adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent within the therapeutic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean INR value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of appointments per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Composite renal outcome event rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Major adverse cardiovascular event rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Depressive symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: tuberculosis outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-rated productivity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: ACT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: amount of added heparin during CPB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: anti-PRP antibody titres > or = 1.0 microgram/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-PRP antibody titres > or = 0.15 microgram/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: vaccine-related elevated temperature (> or = 38 degrees C)
Endpoint domain: Adverse events/effects
Primary endpoint: circuit survival time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of filter failure
Endpoint domain: Adverse events/effects
Primary endpoint: Parental Health-Related Quality of Life (HRQoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of thromboembolic diseases
Endpoint domain: Adverse events/effects
Primary endpoint: binocular naked vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days to extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days to intensive care discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days to hospital discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: objective response rate
Endpoint domain: Physiological/clinical